AVEO Pharmaceuticals Announces Oral Presentation of Data from AV-951 Phase 2 Clinical Trial at the 2009 Genitourinary Symposium

Back To Press & Events


CAMBRIDGE, Mass. Feb 11, 2009 - AVEO Pharmaceuticals, Inc. today announced that interim safety and efficacy results from the Phase 2 clinical trial of its lead product AV-951 – a novel, highly potent and selective triple VEGF receptor inhibitor – will be presented during an oral abstract session at the 2009 Genitourinary (GU) Cancers Symposium. This multidisciplinary symposium, co-sponsored by the American Society of Clinical Oncology, the American Society for Therapeutic Radiology and Oncology, and the Society of Surgical Oncology, is being held February 26-28, 2009 at the Orlando World Center Marriott Resort & Convention Center in Orlando, FL.

Interim safety and efficacy data from the study will be presented at the GU Cancers Symposium by Pankaj Bhargava, M.D., vice president, clinical research for AVEO, during the renal cell cancer oral abstract session taking place on Saturday, February 28, from 1:30 p.m. - 3:00 p.m. The company plans to present complete results from the trial at an upcoming medical meeting later this year.

Data from this presentation, titled “Activity and safety of AV-951, a potent and selective VEGFR1, 2 and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC): Interim results of a Phase 2 randomized discontinuation trial,” will also be on view at the GU Cancers Symposium as part of the renal cell cancer general poster session E and poster walk on Saturday, February 28, from 12:30 p.m. - 1:30 p.m.

“We are very pleased to be presenting interim Phase 2 trial results for AV-951 at the upcoming GU Cancers Symposium,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “This Phase 2 trial of AV-951 for the treatment of patients with metastatic renal cell carcinoma (mRCC) exceeded enrollment goals with more than 270 patients participating. We believe the high level of investigator and patient interest suggests a significant market opportunity for a more potent and selective VEGF receptor inhibitor such as AV-951 and we look forward to sharing an early look into the Phase 2 results with the oncology community.”

Share On Twitter Linkedin